Imcyse
Developing active and specific immunotherapies aimed at treating and curing severe chronic diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€85—128m (Dealroom.co estimates Feb 2021.)
Company register number 0828.385.542
Liège Liège (HQ)
Financials
Estimates*
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | <1m | <1m | 1.0m | 1.1m | 1.5m |
| % growth | - | - | - | 444 % | 126 % | 4 % | 44 % |
| EBITDA | (1.1m) | (6.0m) | (2.3m) | (16.1m) | (3.4m) | - | - |
| % EBITDA margin | - | - | (2796 %) | (3545 %) | (328 %) | - | - |
| Profit | (11.8m) | (4.0m) | (5.7m) | (18.6m) | (13.2m) | (32.8m) | (6.2m) |
| % profit margin | - | - | (6817 %) | (4099 %) | (1291 %) | (3082 %) | (408 %) |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
* | €28.0m | Series B | |
€4.6m | Grant | ||
€2.0m | Debt | ||
€21.3m | Series B | ||
| Total Funding | €53.9m | ||
Related Content
Recent News about Imcyse
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.